INC Research Expands Infectious Diseases Team to Support Global Vaccine Development Research
(Thomson Reuters ONE) -
Dr. Frederick Young to Lead Company's Infectious Diseases Therapeutic Unit
Raleigh, N.C., April 24, 2012 - INC Research, LLC, a therapeutically focused
clinical research organization (CRO) with a Trusted Process(®) for delivering
reliable results, today announced Frederick Young, PhD, has joined its
Infectious Diseases leadership team as vice president, Infectious Diseases. Dr.
Young will leverage his extensive clinical research and development expertise to
lead the Company's infectious diseases therapeutic unit globally.
"Antibiotics and other antimicrobials have played a critical role in the fight
against infectious diseases, but further discovery and evaluation of new
treatments is still needed," said Patricia Monteforte, executive vice president
and general manager, General Medicine, INC Research. "We've become a leader in
infectious diseases research by having a therapeutically-focused team with
experience in all stages and disciplines associated with the development of
anti-infectives. With the addition of Frederick, INC Research is positioned to
expand this therapeutic unit even further with experienced resources to support
and advance our customers' research and development."
Prior to joining INC Research, Dr. Young was vice president of strategic
programs at ICON, where he was a Strategic Account Program Leader and head of
the Strategic Programs Group.. His experience also includes 12 years with
Novartis in a number of positions of increasing responsibility, including
clinical research scientist, executive director, project leader and vice
president/global program head. Dr. Young received his undergraduate degree from
Emory University, earned his doctorate in chemistry from Georgia Institute of
Technology and was awarded a master's degree in business administration from
Rutgers University.
INC Research's Infectious Disease team has experience in all stages of
infectious disease research from initial clinical plan development to Phase I
through Phase IV study conduct to the filing of INDs, NDAs, sNDAs and ex-U.S.
submissions. The team's experience spans both pediatric and adult trials of all
levels of complexity, from Phase I to highly-complex Phase II and III clinical
trials, and from treating everyday infections to fighting highly-resistant
pathogens in an intensive care setting. For more information on INC Research's
therapeutic expertise in Infectious Diseases, click here. To read therapeutic
case studies on infectious diseases, click here.
About INC Research
INC Research is a therapeutically focused clinical research organization with a
high-performance reputation for conducting global clinical development
programs of the highest integrity. Pharmaceutical and biotechnology companies
look to INC Research for a complete range of customized Phase I through Phase IV
programs in all therapeutic areas and innovative pediatric and women's health
trials. The Company's Trusted Process(®) methodology and therapeutic foresight
lead customers to more confident, better-informed drug and device development
decisions. INC Research is headquartered in Raleigh, NC. For more information,
please visit www.incresearch.com or follow us at (at)inc_research.
CONTACT: Lori Dorer, Media, (513) 345-1685
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: INC RESEARCH, LLC via Thomson Reuters ONE
[HUG#1605239]
Unternehmensinformation / Kurzprofil:
Datum: 24.04.2012 - 16:17 Uhr
Sprache: Deutsch
News-ID 138754
Anzahl Zeichen: 4171
contact information:
Town:
Raleigh
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 246 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"INC Research Expands Infectious Diseases Team to Support Global Vaccine Development Research"
steht unter der journalistisch-redaktionellen Verantwortung von
INC RESEARCH, LLC (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
